| Document |
Document Title |
|
WO/1991/019978A1 |
Method using tetra-aryl porphyrins for and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine as a fluorescent tracer for cancers of the lung, and as a radiotracer therefor as a complex with 67Cu. The latter complex also provid...
|
|
WO/1991/019516A1 |
The invention relates to a metal-radionuclide complex comprising isonitrile ligands, said complex having general formula (I), wherein M is a metal-radionuclide selected from radioisotopes of Tc, Ru, Fe, Cr, Mn, Cu, Pb, Ga, As and In; R1 ...
|
|
WO/1991/019977A1 |
Method using tetra-aryl porphyrins for and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine as a fluorescent tracer for cancers of the lung, and as a radiotracer therefor as a complex with 67Cu. The latter complex also provid...
|
|
WO/1991/018868A1 |
The invention relates to a method for the treatment or prophylaxis of psychosis, depression, hypertension, or anxiety in an animal by administering an effective amount of an N,N'-disubstituted guanidine or 2-imino-imidazolidine having a ...
|
|
WO/1991/017999A1 |
The invention relates to a method for labelling substances, including cells such as blood cells, which contain one or more amino groups, with a radioisotope, the substance to be labelled being combined in the presence of a reductor with ...
|
|
WO/1991/016076A1 |
The invention relates to a method of preparing a radiolabeled technetium complex by bringing together a pertechnetate solution in a complex-forming reaction with a compound of general formula (I) wherein R1-R12 independently represent H,...
|
|
WO/1991/015858A1 |
Isotopically labeled compounds are prepared by introducing tritium radiolabel or deuterium label into organic compounds having a reducible site. The process comprises reacting an organic solvented solution of an alkali metal alkyl with a...
|
|
WO/1991/014459A1 |
The subject matter of the present invention relates to bifunctional cyclohexyl DTPA ligands and methods for utilizing these compounds.
|
|
WO/1991/008180A1 |
Deuterized 2,3,3-trihalogeno 2-fluoro 1-propanols of formula (I):DCX1X2-CFX3-CD2OR1 wherein X1, X2 and X3, which may be the same or different, represent a fluorine, chlorine or bromine atom, and R1 is a hydrogen or deuterium atom. These ...
|
|
WO/1990/015626A1 |
A method for radiolabelling a protein with a radioisotope of technetium or rhenium comprises the steps of contacting a solution of a protein comprising a plurality of adjacent free sulfhydryl groups, or in particular cases, intact protei...
|
|
WO/1990/014881A2 |
A new series of bifunctional chelating agents useful for attaching metal ions to proteins, polypeptides and other polymers and methods for their preparation are described. These reagents are unique in their ability to bind a variety of m...
|
|
WO/1990/013530A1 |
The process of the present invention includes preparing a first aqueous solution of rhenium in the form of radioactive perrhenate, wherein the concentration of rhenium in said solution is within the range of about 5 x 10-6 M to about 2 x...
|
|
WO/1990/012096A1 |
A method is provided for enhancing transmembrane transport of exogenous molecules. The method comprises contacting a membrane of a living cell with a complex formed between said molecules and ligands selected from biotin, biotin analogs ...
|
|
WO/1990/009170A2 |
The invention concerns agents for diagnosing and treating malignant melanomas, of general formula (I), in which X denotes a hydrogen or halogen atom, Y denotes a Z-CONH-, Z-O-, Z-S(O)-n1 group, n1 being equal to 0, 1, 2 or 3, a Z-SO2-NH-...
|
|
WO/1990/006776A1 |
Particle emitting radionuclides, e.g. Samarium-153 have been complexed with certain macrocyclic aminophosphonic acids wherein the nitrogen and phosphorus are interconnected by an alkylene group or substituted alkylene group. A compositio...
|
|
WO/1989/011876A1 |
Radiohalogenated compounds which are useful as intermediates for preparing radiohalogenated antibody conjugates in which the radiohalogenated compound is site specifically attached to an oxidized carbohydrate moiety of an antibody or ant...
|
|
WO/1989/008657A2 |
Preparation of 99m technetium or 186 rhenium or 188 rhenium compounds usable as radiopharmaceutical products. To obtain said preparation an oxygenated compound of 99mTc, 186Re or 188Re, for example an ammonium or alcaline metal pertechne...
|
|
WO/1989/007106A1 |
The method of making radioiodinated pyrimidine nucleoside or nucleotide which comprises contacting a water-insoluble halomercuri pyrimidine nucleoside or nucleotide with an aqueous medium containing a dissolved radioactive iodide ion and...
|
|
WO/1989/003388A1 |
The invention concerns cationic complexes of Technetium-99m with bidentate ligands (L), including complexes having the formulae [Tc(NO) X L2]+ and [Tc L3]+, which are of interest as heart imaging agents. The ligands are characterized by ...
|
|
WO/1989/002433A1 |
Tris(isonitrile)copper(I) complex salts with anions selected from BF4, PF6, Cl04, I, Br, Cl and CF3COO are useful in preparing radionuclide complexes rapidly at room temperature. Preferred isonitrile ligands are ether isonitriles. The tr...
|
|
WO/1988/008720A1 |
Complexes useful as radiopharmaceuticals contain the 99mTc-NO moiety and a ligand which confers biological target-seeking properties on the complex. Preferred are mono-cationic complexes, particularly having the formula: [99mTc(NO)L2X]+,...
|
|
WO/1988/007986A2 |
Compound useful particularly for the treatment by targetted radiotherapy or imaging of cancer, characterized in that the compound is comprised of a molecule susceptible of fixing itself or passing close to the DNA of the target cells, sa...
|
|
WO/1987/001290A1 |
A coordination complex comprising a radionuclide selected from the class consisting of radioactive isotopes of Tc, Ru, Co, Pt and Re and an isonitrile ligand of the formula: (CNX)R, where X is a lower alkyl group having 1 to 4 carbon ato...
|
|
WO/1986/000898A1 |
A dihydropyridine$(1,7)$pyridinium salt type of redox, or chemical, delivery system for the site-specific and/or site-enhanced delivery of a radionuclide to the brain. A chelating agent capable of chelating with a radionuclide and having...
|
|
WO/1986/000897A1 |
A dihydropyridine$(1,7)$pyridinium salt type of redox, or chemical, delivery system for the site-specific and/or site-enhanced delivery of a radio-nuclide to the brain. A chelating agent capable of chelating with a radionuclide and havin...
|
|
WO/1985/005452A1 |
Process for the determination of small quantities of drugs, body substances or other chemical compounds in a biological material, characterized in that the compound to be determined and its deuterised analogue are bound to an antibody in...
|
|
WO/1985/004395A1 |
Compounds with arthropodicidal activity having the general formula (I) and their isomeric forms wherein A represents any group which in association with the remainder of the molecule gives arthropodicidal activity and which may contain a...
|
|
WO/1985/004167A1 |
A process for isotopically labelling certain chemical compounds, with a selected or desired isotopic label comprising first treating a precursor material with the isotopic material to exchange the hydrogen atoms of the precursor material...
|
|
JP7467353B2 |
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises...
|
|
JP2024515062A |
The present invention relates to new deuterated compounds of formula (I) and their use as pharmaceuticals. [Formula 1] [Selection diagram] Figure 1
|
|
JP7441475B2 |
The purpose of the present invention is to provide: a novel deuterated labeling compound; and a production method therefor. The present invention provides: a deuterated labeling compound in which at least position β of a fatty acid is d...
|
|
JP7440208B2 |
The present invention relates to a method of radiochemical synthesis. Novel methods useful in the synthesis of a positron emission tomography (PET) tracer, and novel intermediates useful in said method are provided that have advantages o...
|
|
JP7424574B2 |
To provide a manufacturing method of a radioactive fluorine labeling compound shortening manufacturing time while achieving radioactive fluorination rate similar to or more than conventional methods, and a manufacturing method of a radio...
|
|
JP2024009662A |
[Problem] Excited by a DNP device13Provided is an aromatic compound in which the relaxation time of the C nucleus is longer than conventional ones. [Solution] An aromatic compound composed of stable isotopes, in which two adjacent carbon...
|
|
JP2024004495A |
An object of the present invention is to provide a method for producing a deuterated aromatic compound that can efficiently produce a deuterated aromatic compound with a high degree of deuteration. A method for producing a deuterated aro...
|
|
JP2024004127A |
The present invention provides an oxygen isotope-labeled compound useful as a raw material reagent for an oxygen isotope-labeled α-amino acid equivalent. [Solution] An oxygen isotope-labeled compound represented by formula (1) or formul...
|
|
JP7412487B2 |
A method for preparing a complex comprising a radioisotope of gallium for use in radiotherapy or in a medical imaging procedure, said method comprising adding a gallium radioisotope solution obtained directly from a gallium radionuclide ...
|
|
JP2023552527A |
The present specification provides a method for producing a deuterated anthracene compound, a reaction composition, and a deuterated anthracene compound, which includes a step of reacting a halogenated benzene having at least one deuteri...
|
|
JP2023551058A |
The present invention relates to compounds of formula (I) as defined herein, wherein the ratio of deuterium to protium is greater than that found naturally in hydrogen; It relates to compositions (including pharmaceutical compositions) c...
|
|
JP7386383B2 |
The invention concerns a compound according to following formulawherein R1 is a halogen residue.
|
|
JP7370520B2 |
One embodiment of the present invention relates to novel substances, etc., which are: [1] a compound, etc., represented by formula (A1) or formula (B1); [2] a compound, etc., represented by formula (A2) or formula (B2); [3] a compound, e...
|
|
JP2023156982A |
To provide a method for producing a mixed conductive graphene oxide film and a deuterium selective permeable film having good reproducibility and suitable for practical application.A method for producing a cation-doped graphene oxide mix...
|
|
JP7355801B2 |
Methods for preparing isotopically modified 1,4-diene systems from non-isotopically modified 1,4-dienes involve selective oxidation of one or more bis-allylic position(s), or the preparation of isotopically modified 1,4-diene systems via...
|
|
JP2023539113A |
Hallucinogen and psychotropic compounds, serotonin 5-HT2Uses of such compounds in the treatment of diseases associated with receptors, pharmaceutical compositions and kits, such as tablet compositions, containing such compounds, methods ...
|
|
JP2023537167A |
This specification provides a composition represented by Chemical Formula 1 and containing two or more compounds with different numbers of deuterium substitution, wherein the composition contains two or more compounds with different numb...
|
|
JP2023535330A |
The present specification relates to methods of making deuterated aromatic compounds and deuterated reaction compositions.
|
|
JP2023535329A |
The present specification relates to methods of making deuterated aromatic compounds and deuterated reaction compositions.
|
|
JP2023103205A |
To provide compounds, compositions, medicaments and methods related to treatment of cancers expressing PSMA.For example, compounds of formula (I) or pharmaceutically acceptable salts thereof are presented.SELECTED DRAWING: Figure 7A
|
|
JP2023095257A |
To provide a compound useful for the analysis of a vitamin D compound.For example, an alkyne compound 10 prepared by the following reaction is illustrated.SELECTED DRAWING: None
|
|
JP7299911B2 |
The invention relates to compounds according to the general formula (I) or a pharmaceutically acceptable salt of an inorganic or organic acid, a hydrate, a stereoisomer or a solvate thereof, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 a...
|
